Author

A. Belfiore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:organoid / primary culture· 1 Approach:statistical model· 1

Frequent Co-Authors

G. Pruneri· 2 shared A. J. Nicholls· 1 shared A. Oldani· 1 shared A. Podesta· 1 shared A. Singh· 1 shared C. Coombes· 1 shared C. Davies· 1 shared C. Gemma· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Pruneri

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Decellularized Normal and Tumor Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases

L. Varinelli, M. Guaglio, S. Brich, S. Zanutto, A. Belfiore, F. Zanardi, F. Iannelli, A. Oldani, E. Costa, M. Chighizola, S. P. Minardi, S. Fortuzzi, M. Filugelli, G. Garzone, F. Pisati, , M. Gariboldi

The paper develops 3D organoid cultures using decellularized ECM from colorectal peritoneal metastases to model the metastatic niche and assess chemotherapy response.

bioRxiv · Jul 15, 2021 · PreprintCancer Biology

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

C. Gemma, C. Lai, A. Singh, A. Belfiore, N. Portman, H. Z. Milioli, M. Periyasamy, S. Abuelmaaty, A. J. Nicholls, C. Davies, N. R. Patel, G. Simmons, H. Fan, V. Nguyen, L. Magnani, , S. Ali

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

bioRxiv · Nov 29, 2020Cancer Biology